Navigation Links
Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
Date:9/2/2010

's more fundamental research aims to better understand how antisense oligonucleotides (ONs) and small interfering ribonucleic acids (siRNAs) are naturally taken up by cells and to discover ways by which he may enhance this phenomenon. The identification and exploitation of these uptake mechanisms have the potential to change our way of thinking about delivery of siRNAs and to provide basis for developing novel strategies for medicines based on RNA interference.

In 1992, Professor Leroux earned his B.Pharm from Montreal University and in 1995, his Ph.D. from Geneva University. He has held various positions at the Faculty of Pharmacy at Montreal University, from Assistant Professor to Adjunct Professor. Since 2008, Prof. Leroux has headed the laboratory of Drug Formulation and Delivery at the Institute of Pharmaceutical Sciences at the Swiss Federal Institute of Technology (ETH) Zurich. He is among the major experts on liposomes and nanotechnologies in medicine.

About Debiopharm Group(TM)

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III. Debiopharm is also prepared to consider earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Besides drug development, Debiopharm Group has recently embarked in the field of companion diagnostics with a view to progressing in the area of personalised medicine.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.


'/>"/>

SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Professor-turned-producer learns the movie biz
2. UCF professor develops vaccine to protect against black plague bioterror attack
3. Stuart Parkin first distinguished professor at Eindhoven University of Technology
4. Yale professor T.P. Ma awarded the Connecticut Medal of Technology
5. UCF professor develops vaccine to protect against black plague bioterror attack
6. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
7. Gift Aids Professor's Research into Vein Treatment
8. Thin films research lands engineering professor Air Force Young Investigator Award
9. Nyenrode Honorary Doctorate for Professor Michael E. Porter
10. Professor K. C. Nicolaou Speaks at WuXi AppTec
11. Professors Raphael Haftka and C. T. Sun to receive AIAA-ASC James H. Starnes, Jr. Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015 Biofertilizers stimulate microbial activities in ... and phosphorous through the activities in the soil or ... due to the stress on reducing environmental pollution and ... report defines and segments the bio fertilizers market with ...
(Date:1/22/2015)... Eckert & Ziegler Vitalea Science (EZVS), ... to the pharmaceutical and biotech industry, has announced that ... the position of Director of Science & Technology. , ... experience in drug metabolism and bioanalysis to EZVS in ...
(Date:1/22/2015)... 22, 2015 GEA Niro Soavi the ... laboratory homogenizer, the PandaPLUS 2000, which is ideal for ... and cell disruption . This compact laboratory homogenizer ... juices, liquid food, food additives and ingredients as well ...
(Date:1/22/2015)... 22, 2015 The laboratory information management ... witnessed a number of technological advancements due to factors ... growing need to integrate healthcare systems, and increasing government ... in system integration. Key players in the market focus ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... conducted pursuant to Special Protocol Assessment with the Food ... - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: ... oncology and endocrine therapy, today announced the initiation, by ... a Phase 3 registration clinical trial for perifosine (KRX-0401), ...
... The American ... 22-25, 2010 at the Grand Hyatt Hotel in San Antonio, Texas. To further impact the ... to announce that the 2010 AFS Annual Technical Conference will be co-located with the 2010 ... ...
... , , , , , ... Sky One,Medical, Inc. ("China Sky One Medical" or "the ... company developing and producing,over-the-counter drugs in the People,s Republic ... medicines that will be included in the 2009,Edition of ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 2AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 3AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 4AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma 5American Filtration and Separations Society to Hold 23nd Annual Technical Conference 2American Filtration and Separations Society to Hold 23nd Annual Technical Conference 3American Filtration and Separations Society to Hold 23nd Annual Technical Conference 4China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 2China Sky Medical, Inc. Has 30 Medicines that will Be Included in China's National Insurance Directory 3
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
(Date:1/22/2015)... YORK and POINT ROBERTS, Washington ... news source covering leading sectors including technology and tech stocks, ... Privacy marketplace featuring master pickpocket and security consultant Apollo ... is stolen and talks about the Wocket™ biometric smart wallet, ...
(Date:1/22/2015)... January 22, 2015 , ... The European Patent Office to present a video retrospective ... nominations to be featured: Christofer Toumazou and Sophie ... finalists and winners of the Award   Starting on ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... of Environment and Hydrology (CEH) have investigated the ecology ... as parasites inside colonies of Myrmica ants, where they ... the peculiar features of this species' ecology is that ... one year. The rest are inactive in the first ...
... (HHMI) international research scholar Peter St George-Hyslop have identified ... common form of Alzheimer's disease. The research implicates a ... after age 65. , In an advance online ... George-Hyslop and colleagues connected the gene to the disease ...
... cancer-suppressing gene has been successfully delivered into the tumors ... administered lipid nanoparticle in a phase I clinical trial at ... The gene, FUS1, also was found to be active ... treated 13 patients in this first-in-human study and we've seen ...
Cached Biology News:Some caterpillers just don't want to grow up 2Scientists discover a new risk factor for Alzheimer's 2Scientists discover a new risk factor for Alzheimer's 3Intravenous nanoparticle gene therapy shows activity in stage IV lung cancer 2
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
For the development of an immunoprecipitation assay to measure Chk1 kinase activity in cell lysates....
Bovine Serum Albumin Peroxidase Stabilizer Solution, 1 L...
Homo sapiens olfactomedin 1, transcript variant 3...
Biology Products: